Futuros
Aceda a centenas de contratos perpétuos
TradFi
Ouro
Plataforma de ativos tradicionais globais
Opções
Hot
Negoceie Opções Vanilla ao estilo europeu
Conta Unificada
Maximize a eficiência do seu capital
Negociação de demonstração
Introdução à negociação de futuros
Prepare-se para a sua negociação de futuros
Eventos de futuros
Participe em eventos para recompensas
Negociação de demonstração
Utilize fundos virtuais para experimentar uma negociação sem riscos
Lançamento
CandyDrop
Recolher doces para ganhar airdrops
Launchpool
Faça staking rapidamente, ganhe potenciais novos tokens
HODLer Airdrop
Detenha GT e obtenha airdrops maciços de graça
Launchpad
Chegue cedo ao próximo grande projeto de tokens
Pontos Alpha
Negoceie ativos on-chain para airdrops
Pontos de futuros
Ganhe pontos de futuros e receba recompensas de airdrop
Investimento
Simple Earn
Ganhe juros com tokens inativos
Investimento automático
Invista automaticamente de forma regular.
Investimento Duplo
Aproveite a volatilidade do mercado
Soft Staking
Ganhe recompensas com staking flexível
Empréstimo de criptomoedas
0 Fees
Dê em garantia uma criptomoeda para pedir outra emprestada
Centro de empréstimos
Centro de empréstimos integrado
Mais
Orexin-2 Receptor Data Reinforces a Positive Outlook for Centessa (CNTA)
Orexin-2 Receptor Data Reinforces a Positive Outlook for Centessa (CNTA)
Muhammad Ali Khalid
Tue, February 17, 2026 at 3:00 AM GMT+9 2 min read
In this article:
CNTA
TFC
Centessa Pharmaceuticals (NASDAQ:CNTA) is one of the 17 biotechnology stocks with more than 50% upside.
On January 29, Danielle Brill from Truist Financial raised her price target on Centessa Pharmaceuticals (NASDAQ:CNTA) from $33 to $38 and assigned a Buy rating to the stock. Her rating came after Truist Financial updated its projections following a thorough reassessment of the current data regarding the orexin-2 receptor agonist class.
M. A. Arkhipov/Shutterstock.com
On January 16, Biren Amin from Piper Sandler maintained an Overweight rating on Centessa Pharmaceuticals (NASDAQ:CNTA). He forecasted a $38 price target for the stock, which implied a 57% upside potential.
Amin highlighted two major catalysts expected this quarter. These include the planned initiation of Phase 3 trials for ORX750 across NT1, NT2, and IH, along with additional findings from the CRYSTAL-1 Phase 2 study. The analyst is optimistic about idiopathic hypersomnia as it may represent a larger and potentially underappreciated market opportunity.
Centessa Pharmaceuticals (NASDAQ:CNTA) is involved in the discovery and development of transformative medicines for neurological and neurodegenerative diseases. The company operates under an asset-centric Research and Development model, with a portfolio of subsidiaries that support specialized research programs. These individual programs are treated as separate entities to ensure highly efficient, data-driven decision-making.
While we acknowledge the potential of CNTA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.
Disclosure: None. This article is originally published at Insider Monkey.
Terms and Privacy Policy
Privacy Dashboard
More Info